VRTX · 10-Q · 2026Q3

VERTEX PHARMACEUTICALS INC / MA

Filed 2026-11-03 · Healthcare · View original filing on EDGAR

Ranked Events

• Operating Expense TrendsImportance 77 · Surprise 82
  Research and development expense increased 35% to $1,320.6 million in the third quarter and 12% to $3,276.0 million in the first nine months of 2026.,Development expense rose 42% to $1,091.6 million in the third quarter, including $235.3 million of compensation for cash-settled unvested Crinetics equity awards and higher outsourced services and other direct expenses.,Selling, general and administrative expense increased 90% to $844.1 million in the third quarter and 52% to $1,920.0 million in the first nine months, including $203.0 million of Crinetics-related compensation and transaction costs.,The company also cited increased headcount and commercial investment for JOURNAVX and the anticipated povetacicept IgAN launch; nine-month AIPR&D declined 18% to $62.5 million.
• Liquidity and Debt PositionImportance 73 · Surprise 66
  Cash, cash equivalents and marketable securities totaled $9,821.2 million at September 30, 2026, down 20% from $12,320.4 million at December 31, 2025, primarily following the Crinetics acquisition and share repurchases.,Working capital decreased 9% to $6,686.0 million, reflecting $1.0 billion of short-term debt and lower cash and short-term securities, partly offset by acquired inventory.,Vertex borrowed the full $4.5 billion under its 2026 Term Loan in September; repayment is scheduled as $1.0 billion in August 2027, $1.0 billion in September 2028 and $2.5 billion in August 2029.,Operating cash flow was $3,196.6 million in the first nine months of 2026, while investing cash flow used $6,578.3 million and financing cash flow provided $3,331.4 million; Vertex said available funds and operating cash flows are expected to fund operations for at least 12 months.
• CASGEVY Pediatric Market ExpansionImportance 72 · Surprise 100
  CASGEVY generated $99.2 million in third-quarter 2026 product revenue, up 30% from the second quarter and more than 400% year over year. The FDA approved CASGEVY for children aged two and older with sickle cell disease…
• Crinetics Acquisition FinancingImportance 71 · Surprise 60
  In September 2026, Vertex acquired Crinetics for $85.00 per share in cash, a total equity value of $10.0 billion, or $9.0 billion net of acquired cash, cash equivalents and marketable securities. Vertex funded the…
• Acquisition / Partnership / DivestitureImportance 71 · Surprise 60
  Vertex completed its acquisition of Crinetics in September 2026 for $85.00 per share in cash, representing $10.0 billion of equity value and $9.0 billion net of acquired cash, cash equivalents and marketable securities.,Vertex financed the acquisition using cash and marketable securities plus $4.5 billion borrowed under the 2026 Term Loan.,The business combination added $8.1 billion of intangible assets to the balance sheet and brought PALSONIFY into Vertex's commercial portfolio.,Vertex recorded $62.5 million of AIPR&D in the first nine months of 2026, including upfront, contingent milestone or other payments under business development transactions.
• Market Demand TrendsImportance 60 · Surprise 40
  Vertex reported continued growth in cystic fibrosis (CF) therapies and expanding contributions from CASGEVY, JOURNAVX, and PALSONIFY, with total product revenues up 11% in the first nine months of 2026. CF remains the…
• Geographic Market CommentaryImportance 57 · Surprise 40
  In the first nine months of 2026, U.S. total revenue increased 9%, supported by strong patient demand, new ALYFTREK initiations, higher realized net prices in CF, and contributions from CASGEVY, JOURNAVX, and…
• Gross Margin DriversImportance 54 · Surprise 40
  Cost of sales was $526.1 million in the third quarter of 2026, up 27% year over year, and $1,408.1 million for the first nine months, up 19%.,Cost of sales rose to 15.3% of net product revenue in the third quarter and 14.4% for the first nine months, compared with 13.5% in each 2025 period.,The higher cost ratio reflected product mix and Crinetics-related PALSONIFY amortization of $15.3 million and acquired inventory step-up expense of $5.4 million for September, partly offset by lower blended CF royalty rates.,Management said PALSONIFY amortization and acquired inventory step-up expenses will increase in future quarters.
• Revenue Performance and MixImportance 54 · Surprise 40
  Third-quarter 2026 total revenue was $3,440.8 million, up 12% from $3,076.4 million, while nine-month revenue rose 11% to $9,761.6 million from $8,811.3 million.,Nine-month CF product revenue increased 8% to $9,396.1 million; ALYFTREK revenue grew 272% to $1,703.8 million, offsetting a 6% decline in TRIKAFTA/KAFTRIO to $7,288.8 million and a 17% decline in other CF products to $403.5 million.,Nine-month CASGEVY revenue increased 255% to $218.5 million and JOURNAVX revenue increased 316% to $136.9 million, while PALSONIFY contributed $10.1 million following the September 1, 2026 Crinetics acquisition.,U.S. revenue increased 9% to $6,001.4 million in the first nine months, and ex-U.S. revenue increased 13% to $3,760.2 million, with ex-U.S. growth also benefiting from favorable foreign exchange.
• JOURNAVX Demand and AccessImportance 51 · Surprise 64
  More than 750,000 JOURNAVX prescriptions were filled across hospital and retail settings in the third quarter of 2026, an increase of more than 40% from the second quarter and more than four times the 170,000…
• Povetacicept Regulatory ReviewImportance 47 · Surprise 60
  The FDA placed Vertex’s biologics license application for accelerated approval of povetacicept in adults with IgA nephropathy (IgAN) under priority review, with a target action date of November 30, 2026. If approved,…
• ALYFTREK Royalty ArbitrationImportance 40 · Surprise 42
  On October 10, 2025, Royalty Pharma and the Cystic Fibrosis Foundation initiated confidential arbitration over royalties on ALYFTREK sales. Vertex maintains that the royalty burden is 4%, while the claimants allege it…
• Regulatory Approval MilestonesImportance 34 · Surprise 42
  Vertex reported that PALSONIFY was approved in the European Union in April 2026 and expects to begin launches in European markets in the second half of 2027. Its regulatory submission in Japan was completed in April…
• IgAN Launch and DifferentiationImportance 34 · Surprise 42
  Vertex is preparing for a potential launch of povetacicept for IgA nephropathy (IgAN), positioning it as a potentially best-in-class dual inhibitor of BAFF and APRIL cytokines to control B-cell activity. The biologics…
• PALSONIFY Market AdoptionImportance 34 · Surprise 42
  PALSONIFY is a once-daily oral treatment approved in the U.S. for adults with acromegaly who had an inadequate response to surgery or cannot undergo surgery; Vertex estimates it is an option for 12,000 U.S. adults.…
• Capital Return ProgramImportance 32 · Surprise 24
  Vertex repurchased common stock during the first nine months of 2026, contributing to financing cash outflows alongside the Crinetics acquisition financing.,As of September 30, 2026, $2.5 billion remained available under the share repurchase authorization approved by the Board in May 2025.,The authorization has no expiration date and can be discontinued at any time.,Vertex expects to fund future repurchases with a combination of cash on hand and cash generated from operations.
• Income Tax Rate ChangesImportance 30 · Surprise 40
  Vertex's effective tax rate was 18.8% for the first nine months of 2026, below the U.S. statutory rate.,A research and development tax credit study completed in the third quarter of 2026 and excess tax benefits from stock-based compensation reduced the 2026 effective tax rate.,The comparable first-nine-month 2025 effective tax rate was 16.6%, also below the U.S. statutory rate, due to an R&D tax credit study, stock-based compensation tax benefits and greater foreign tax credit utilization, partly offset by uncertain tax-position changes.
• FX / Currency ImpactImportance 23 · Surprise 22
  Vertex attributed part of its 16% third-quarter 2026 and 13% first-nine-months 2026 ex-U.S. revenue growth to favorable foreign-exchange impacts. Ex-U.S. revenue was $1,271.7 million in the quarter and $3,760.2 million…
• Guidance / OutlookImportance 23 · Surprise 24
  Vertex expects to complete enrollment in both Phase 3 trials of suzetrigine for diabetic peripheral neuropathy by the end of 2026 and share results in mid-2027. It expects to complete enrollment in the Phase 3…
• Supply Chain ConstraintsImportance 10 · Surprise 6
  Vertex relies on a global network of third parties, including some in China, alongside internal capabilities to manufacture and distribute commercial products and clinical-trial candidates. It adapts supply chains for…

Revenue by Product (in millions)

Revenue by Geography (in millions)